Relationship between selection of dosage forms of vitamin D receptor activators and short-term survival of patients on hemodialysis

References

• Shoben AB, Rudser KD, de Boer IH, et al. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol. 2008;19(8):1613–1619.
   PubMedGoogle Scholar
• Kovesdy CP, Ahmadzadeh S, Anderson JE, et al. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med. 2008;168(4):397–403.
   PubMedGoogle Scholar
• Shoji T, Shinohara K, Kimoto E, et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant. 2004;19(1):179–184.
   PubMed Web of Science ®Google Scholar
• Sugiura S, Inaguma D, Kitagawa A, et al. Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events. Clin Exp Nephrol. 2010;14(1):43–50.
   PubMedGoogle Scholar
• Duranton F, Rodriguez-Ortiz ME, Duny Y, et al. Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis. Am J Nephrol. 2013;37(3):239–248.
   PubMed Web of Science ®Google Scholar
• Papadimitropoulos E, Wells G, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev. 2002;23(4):560–569.
   PubMed Web of Science ®Google Scholar
• Kumar VA, Kujubu DA, Sim JJ, et al. Vitamin D supplementation and recombinant human erythropoietin utilization in vitamin D-deficient hemodialysis patients. J Nephrol. 2011;24(1):98–105.
   PubMedGoogle Scholar
• Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110(2):229–238.
   PubMed Web of Science ®Google Scholar
• Zhou C, Lu F, Cao K, et al. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int. 2008;74(2):170–179.
   PubMed Web of Science ®Google Scholar
• Bodyak N, Ayus JC, Achinger S, et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in dahl salt-sensitive animals. Proc Natl Acad Sci USA. 2007;104(43):16810–16815.
   PubMedGoogle Scholar
• John GB, Cheng CY, Kuro-o M. Role of klotho in aging, phosphate metabolism, and CKD. Am J Kidney Dis. 2011;58(1):127–134.
   PubMed Web of Science ®Google Scholar
• Al-Sofiani ME, Jammah A, Racz M, et al. Effect of vitamin D supplementation on glucose control and inflammatory response in type II diabetes: a double blind, randomized clinical trial. Int J Endocrinol Metab. 2015;13(1):e22604.
   PubMed Web of Science ®Google Scholar
• Sassi F, Tamone C, D’Amelio P. Vitamin D: nutrient, hormone, and immunomodulator. Nutrients. 2018;10(11):1656.
   PubMed Web of Science ®Google Scholar
• Wu-Wong JR, Melnick J. Vascular calcification in chronic kidney failure: role of vitamin D receptor. Curr Op Investig Drugs. 2007;8(3):237–247.
   PubMedGoogle Scholar
• Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31–38.
   PubMed Web of Science ®Google Scholar
• Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–281.
   PubMed Web of Science ®Google Scholar
• Kim CS, Kim SW. Vitamin D and chronic kidney disease. Korean J Intern Med. 2014;29(4):416–427.
   PubMedGoogle Scholar
• Hossein-Nezhad A, Holick MF. Vitamin D for health: a global perspective. Mayo Clin Proc. 2013;88(7):720–755.
   PubMed Web of Science ®Google Scholar
• Fukagawa M, Yokoyama K, Koiwa F, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial. 2013;17(3):247–288.
   PubMed Web of Science ®Google Scholar
• Group KDIGOKC-MUW. Kdigo 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (ckd-mbd). Kidney Int Supple. 2017;7(1):1–59.
   Google Scholar
• Masakane IT, Nakai S, et al. Annual dialysis data report 2015, JSDT registry. Jpn Soc Dial Ther. 2017;50(1):1–62.
   Google Scholar
• Hishida M, Tamai H, Morinaga T, et al. Aichi cohort study of the prognosis in patients newly initiated into dialysis (AICOPP): baseline characteristics and trends observed in diabetic nephropathy. Clin Exp Nephrol. 2016;20(5):795–807.
   PubMed Web of Science ®Google Scholar
• Imai E, Horio M, Nitta K, et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol. 2007;11(1):41–50.
   PubMedGoogle Scholar
• Payne RB, Little AJ, Williams RB, et al. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J. 1973;4(5893):643–646.
   PubMedGoogle Scholar
• Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349(5):446–456.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.
   PubMed Web of Science ®Google Scholar
• Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int. 2008;74(8):1070–1078.
   PubMedGoogle Scholar
• Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005;16(4):1115–1125.
   PubMedGoogle Scholar
• Grubler MR, Gaksch M, Kienreich K, et al. Effects of vitamin D supplementation on plasma aldosterone and renin-A randomized placebo-controlled trial. J Clin Hypertens. 2016;18(7):608–613.
   Google Scholar
• Li YC. Discovery of vitamin D hormone as a negative regulator of the renin-angiotensin system. Clin Chem. 2014;60(3):561–562.
   PubMedGoogle Scholar
• Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012;307(7):674–684.
   PubMed Web of Science ®Google Scholar
• Wang AY, Fang F, Chan J, et al. Effect of paricalcitol on left ventricular mass and function in CKD–the OPERA trial. J Am Soc Nephrol. 2014;25(1):175–186.
   PubMed Web of Science ®Google Scholar
• Tamez H, Zoccali C, Packham D, et al. Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J. 2012;164(6):902–909.
   PubMedGoogle Scholar
• Obi Y, Hamano T, Wada A, et al. Vitamin D receptor activator use and cause-specific death among dialysis patients: a nationwide cohort study using coarsened exact matching. Sci Rep. 2017;7:41170.
   PubMedGoogle Scholar
• Shoji T, Inaba M, Fukagawa M, et al. Effect of oral alfacalcidol on clinical outcomes in patients without secondary hyperparathyroidism receiving maintenance hemodialysis the J-DAVID randomized clinical trial. JAMA. 2018;320(22):2325–2334.
   PubMed Web of Science ®Google Scholar
• Thacher TD, Clarke BL. Vitamin D insufficiency. Mayo Clin Proc. 2011;86(1):50–60.
   PubMed Web of Science ®Google Scholar
• Melamed ML, Thadhani RI. Vitamin D therapy in chronic kidney disease and end stage renal disease. Clin J Am Soc Nephrol. 2012;7(2):358–365.
   PubMed Web of Science ®Google Scholar
• Dusso AS. Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation. Kidney Int Suppl. 2011;1(4):136–141.
   Web of Science ®Google Scholar
• Gunta SS, Thadhani RI, Mak RH. The effect of vitamin D status on risk factors for cardiovascular disease. Nat Rev Nephrol. 2013;9(6):337–347.
   PubMed Web of Science ®Google Scholar
• Guideline Working Group. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial. 2008;12(6):514–525.
   PubMedGoogle Scholar
• Patel L, Bernard LM, Elder GJ. Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol. 2016;11(2):232–244.
   PubMedGoogle Scholar
• Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and Meta-analysis. Lancet. 2013;382(9900):1268–1277.
   PubMed Web of Science ®Google Scholar
• Wheeler DC, London GM, Parfrey PS, et al. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation of cinacalcet HCl therapy to lower CardioVascular events (EVOLVE) trial. J Am Heart Assoc. 2014;3(6):e001363.
   PubMed Web of Science ®Google Scholar
• Friedl C, Reibnegger G, Kramar R, et al. Mortality in dialysis patients with cinacalcet use: a large observational registry study. Eur J Intern Med. 2017;42:89–95.
   PubMedGoogle Scholar